文献速递艾滋病与性传播感染

老年HIV患者抗逆转录病毒治疗:GEPPO队列研究

Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

GEPPO是一项前瞻性观察性多中心队列,纳入1222例≥65岁HIV感染者(中位年龄70岁),旨在描述意大利感染科医生实际使用的抗逆转录病毒处方策略。结果显示66.4%使用三联疗法,25.3%使用双药疗法,6.5%使用单药疗法,1.64%使用超过三药的mega-ART;多病共存(64%)和多重用药(37%)可预测非传统方案的使用。

要点

  • 老年HIV患者中非传统抗逆转录病毒方案比例较高,提示医生根据年龄、HIV病程、多病共存和多重用药调整方案。
  • 多病共存(≥3种非传染性疾病)和多重用药(≥5种长期用药)可预测单药/双药、NRTI节省和TDF节省方案的使用。
  • 女性性别和年龄是使用非增强型抗逆转录病毒方案的预测因素。

核心结论

  • 老年HIV患者中非传统抗逆转录病毒方案使用率高,提示临床医生根据年龄、HIV病程、多病共存和多重用药进行个体化方案调整。

研究设计与样本

  • GEPPO为前瞻性观察性多中心队列,纳入HIV感染的老年患者;本分析为横断面研究,描述≥65岁老年HIV人群当前的抗逆转录病毒方案。
  • 共纳入1222例HIV阳性患者,中位年龄70岁,女性占16%,HIV感染中位病程17年,335例感染超过20年。

主要发现

  • 多病共存(≥3种非传染性疾病)患病率为64%,多重用药(≥5种长期用药)为37%。
  • 治疗方案中三联疗法占66.4%,双药疗法占25.3%,单药疗法占6.5%,超过三药的mega-ART占1.64%。
  • 多因素logistic回归显示,多病共存和多重用药可预测单药-双药、NRTI节省和TDF节省联合方案的使用。
  • 女性性别和年龄是非增强型抗逆转录病毒方案的预测因素。

关键数值与推荐

  • 多病共存定义为存在三种或以上非传染性疾病。
  • 多重用药定义为五种或以上药物长期使用。
  • 多药方案(MDRs)包括三联或mega ART组合;少药方案(LDRs)包括少于三种ART药物。

临床怎么用

  • 对老年HIV患者处方时,可结合年龄、HIV病程、多病共存和多重用药情况,考虑非传统ART方案(如双药、单药或节省特定药物的方案)以个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GEPPO is a prospective observational multi-centric cohort including HIV-infected geriatric patients. We hypothesized that the GEPPO cohort may help characterize antiretroviral (ARV) prescribing criteria used in real life by Italian infectious disease (ID) physicians. METHODS: This was a cross-sectional study describing the current ARV regimen in a geriatric HIV population (≥65 years). Antiretroviral strategies were categorized as follows: (i) multidrug regimens (MDRs), which comprised triple or mega ART combinations; (ii) less drug regimens (LDRs), which comprised fewer than three ART compounds. Multi-morbidity (MM) was defined as the presence of three or more non-communicable diseases, and polypharmacy (PP) as the use of five or more medications in chronic use. Four alternative combinations (MM+PP+, MM+PP-, MM-PP+, MM-PP-) were used in logistic regression analyses. RESULTS: A total of 1222 HIV-positive patients were included (median age 70 years). Females composed 16% of the cohort. Median duration of HIV infection was 17 years; 335 population members had been infected for >20 years. MM was present in 64% and PP in 37% of the patients. Treatment consisted of triple therapy in 66.4%, dual therapy in 25.3%, monotherapy in 6.5% and 'mega-ART' with more than three drugs in 1.64% of the patients. In multivariate logistic regression MM and PP were predictive for mono-dual, NRTI-sparing and tenofovir disoproxil fumarate (TDF)-sparing combinations. Female gender and age were predictors of unboosted ARV regimens. CONCLUSIONS: High prevalence of non-conventional ARV regimens in elderly HIV patients suggests that clinicians try to tailor ARV regimens according to age, HIV duration, MM and PP.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nozza S, Malagoli A, Maia L, et al. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017. PMID: 28605493. doi:10.1093/jac/dkx169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。